Mark Sylvester

959 total citations
14 papers, 380 citations indexed

About

Mark Sylvester is a scholar working on Molecular Biology, Molecular Medicine and Pharmacology. According to data from OpenAlex, Mark Sylvester has authored 14 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Molecular Medicine and 4 papers in Pharmacology. Recurrent topics in Mark Sylvester's work include Antibiotic Resistance in Bacteria (5 papers), Bacterial Genetics and Biotechnology (4 papers) and Chemical Synthesis and Analysis (2 papers). Mark Sylvester is often cited by papers focused on Antibiotic Resistance in Bacteria (5 papers), Bacterial Genetics and Biotechnology (4 papers) and Chemical Synthesis and Analysis (2 papers). Mark Sylvester collaborates with scholars based in United States, United Kingdom and Russia. Mark Sylvester's co-authors include Philip D. Edwards, Rubén Tommasi, C Birr, Gaochao Tian, Barry Greenberg, Alita A. Miller, Xiaodong Liu, John R. Zysk, Thomas F. Durand-Réville and Stephen T. Furlong and has published in prestigious journals such as Journal of Biological Chemistry, Bioorganic & Medicinal Chemistry and Current Pharmaceutical Design.

In The Last Decade

Mark Sylvester

14 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Sylvester United States	9	172	94	88	76	61	14	380
Kathleen M. McKenzie United States	8	332 1.9×	22 0.2×	40 0.5×	22 0.3×	56 0.9×	11	439
Jeremy R. Hershfield United States	10	169 1.0×	39 0.4×	32 0.4×	25 0.3×	47 0.8×	14	332
Alexei S. Kazakov Russia	13	579 3.4×	16 0.2×	66 0.8×	56 0.7×	115 1.9×	37	712
Jessica L. Schneck United States	11	263 1.5×	24 0.3×	66 0.8×	12 0.2×	32 0.5×	22	405
Justin Lecher Germany	10	219 1.3×	29 0.3×	17 0.2×	121 1.6×	67 1.1×	14	375
Kyoung‐Jae Choi United States	16	614 3.6×	21 0.2×	33 0.4×	65 0.9×	64 1.0×	27	810
Irene G. Salado Spain	9	176 1.0×	13 0.1×	62 0.7×	41 0.5×	12 0.2×	14	359
Kennosuke Wada Japan	10	266 1.5×	75 0.8×	19 0.2×	77 1.0×	61 1.0×	26	425
Rajan Vyas India	11	349 2.0×	16 0.2×	27 0.3×	35 0.5×	42 0.7×	20	455
Marialuisa Pellegrini‐Calace Italy	14	467 2.7×	17 0.2×	38 0.4×	15 0.2×	39 0.6×	18	568

Countries citing papers authored by Mark Sylvester

Since Specialization

Citations

This map shows the geographic impact of Mark Sylvester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sylvester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sylvester more than expected).

Fields of papers citing papers by Mark Sylvester

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sylvester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sylvester. The network helps show where Mark Sylvester may publish in the future.

Co-authorship network of co-authors of Mark Sylvester

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Sylvester. A scholar is included among the top collaborators of Mark Sylvester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Sylvester. Mark Sylvester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Shapiro, Adam B., Janelle Comita-Prevoir, Jing Zhang, et al.. (2020). N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay. Bioorganic & Medicinal Chemistry. 28(24). 115826–115826. 16 indexed citations

Shapiro, Adam B., Janelle Comita-Prevoir, & Mark Sylvester. (2019). 5-Carboxytetramethylrhodamine-Ampicillin Fluorescence Anisotropy-Based Assay of Escherichia coli Penicillin-Binding Protein 2 Transpeptidase Inhibition. ACS Infectious Diseases. 5(6). 863–872. 10 indexed citations

Sylvester, Mark, et al.. (2018). An amine protecting group deprotectable under nearly neutral oxidative conditions. Beilstein Journal of Organic Chemistry. 14. 1750–1757. 8 indexed citations

Iyer, Ramkumar, Mark Sylvester, Camilo Velez‐Vega, et al.. (2017). Whole-Cell-Based Assay To Evaluate Structure Permeation Relationships for Carbapenem Passage through the Pseudomonas aeruginosa Porin OprD. ACS Infectious Diseases. 3(4). 310–319. 31 indexed citations

Gu, Chungang, Michelle L. Lamb, Jeffrey W. Johannes, et al.. (2016). Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering. Bioorganic & Medicinal Chemistry Letters. 26(19). 4775–4780. 5 indexed citations

Isabella, Vincent M., Arthur J. Campbell, John I. Manchester, et al.. (2015). Toward the Rational Design of Carbapenem Uptake in Pseudomonas aeruginosa. Chemistry & Biology. 22(4). 535–547. 52 indexed citations

Murphy-Benenato, Kerry E., Thomas F. Durand-Réville, Andrew D. Ferguson, et al.. (2015). SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3. ACS Medicinal Chemistry Letters. 6(5). 537–542. 24 indexed citations

Friedman, Harris L., et al.. (2014). Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications. International Journal of Transpersonal Studies. 33(2). 84–140. 35 indexed citations

Shapiro, Adam B., Helen Plant, Jarrod Walsh, et al.. (2014). Discovery of ATP-Competitive Inhibitors of tRNAIle Lysidine Synthetase (TilS) by High-Throughput Screening. SLAS DISCOVERY. 19(8). 1137–1146. 5 indexed citations

10.

Sylvester, Mark, et al.. (2011). Addiction Liability of Pharmacotherapeutic Interventions in Obesity. Current Pharmaceutical Design. 17(12). 1188–1192. 5 indexed citations

11.

Tian, Gaochao, John R. Zysk, Xiaodong Liu, et al.. (2002). Linear Non-competitive Inhibition of Solubilized Human γ-Secretase by Pepstatin A Methylester, L685458, Sulfonamides, and Benzodiazepines. Journal of Biological Chemistry. 277(35). 31499–31505. 116 indexed citations

12.

Furlong, Stephen T., Anand S. Dutta, James J. Gormley, et al.. (2000). C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl α-ketoheterocycles. Immunopharmacology. 48(2). 199–212. 31 indexed citations

13.

Edwards, Philip D., Russell C. Mauger, Kevin M. Cottrell, et al.. (2000). Synthesis and enzymatic evaluation of a P1 arginine aminocoumarin substrate library for trypsin-like serine proteases. Bioorganic & Medicinal Chemistry Letters. 10(20). 2291–2294. 37 indexed citations

14.

Sylvester, Mark, et al.. (2000). Mastering Maya Complete 2. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact